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and meropenem (MER) in critically ill patients.
Patients and methods: Patients were sampled on a daily basis. TZP or MER concentrations were evaluated during
the ﬁrst two days antibiotic therapy. The lower limit of the target range was deﬁned as unbound concentrationsKeywords:Purpose: To evaluate target attainment of empirically dosed continuous infusion piperacillin/tazobactam (TZP)
equaling 4 times the epidemiological cutoff value of P. aeruginosa. The upper limit of the target range was based
on the risk of toxicity, i.e. unbound concentrations N160mg/L for TZP and N 45mg/L forMER.Multivariable logis-
tic regression was used to evaluate factors associated with target attainment.
Results:Data from 253 patients were analyzed. Overall, 76/205 (37.1%) and 36/48 (75%) of the patients receiving
TZP orMER respectively, attained target concentrations. Inmultivariable analysis, estimated creatinine clearance
was identiﬁed as a risk factor for target non-attainment (OR 0.988, 95%CI [0.982;0.994]). Patients receiving MER
were more likely to attain target concentrations compared with patients receiving TZP (OR 6.02, 95%CI
[2.12;18.4]).
Conclusion: Target attainment of empiric antibiotic therapy in critically ill patients was low (37%) for TZP and
moderate (75%) for MER, despite the use of a loading dose and despite optimization of the mode of infusion.
© 2019 Elsevier Inc. All rights reserved.Critically ill patients
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Effective antibiotic therapy for the treatment of infectious diseases in
critically ill patients is paramount to achieve a favorable clinical out-
come. Failure of antibiotic therapy may occur for many reasons, for in-
stance, infection with micro-organisms not susceptible to empirical
therapy, lack of source control, patient-speciﬁc factors such as immuno-
suppression and subtherapeutic antibiotic concentrations [1-3].000, Belgium.
se), alexander.thooft@ugent.be
j.lipman@uq.edu.au (J. Lipman),
ve@uzgent.be (V. Stove),
(J.J. De Waele).From a clinical point of view, empirical antimicrobial drug dosing
regimens should ideally achieve drug concentrations that are high
enough to kill and prevent regrowth of all micro-organisms deemed
susceptible to the drug, immediately after the ﬁrst dose and at least
until microbiology reports of the pathogen are available [4]. Once the
microbiology report of the pathogen is available, changes to the type
of antibiotic and/or, changes to antibiotic dosing can be considered.
Piperacillin/tazobactam (TZP), a penicillin derivative, and mero-
penem(MER), a carbapenem, are beta-lactamantibiotics commonly pre-
scribed to treat serious infections in the ICU. As other beta-lactam
antibiotics, TZP and MER are characterized by a time-dependent mode
of action, i.e. their killing-properties depend on the time (T) free (f) con-
centrations remainabove theminimal inhibitory concentration (MIC), i.e.
%fTNMIC. Currently, experts are advocating for target concentrations of
100% fT≥4 x MIC, i.e. the PK/PD target [5].
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regimens in ICU patients is challenging as the PK of antimicrobial
drugs may be profoundly altered during critical illness. A common oc-
currence in critically ill patients is the ﬁnding of increased renal clear-
ance due to an increased cardiac output and an increased volume of
distribution because of third spacing and hypoalbuminemia. For beta-
lactam antibiotics speciﬁcally, both ﬁndings may substantially lower
antibiotic concentrations [6]. Therefore, empirical dosing in critically
ill patients is likely to be suboptimal when the altered PK of antimicro-
bial drugs is not taken into account. Low antibiotic concentrations have
previously been linked to clinical failure and the emergence of antimi-
crobial resistance [7,8] while high concentrations have been linked to
toxicity, which is mainly neurotoxicity in the case of beta-lactam antibi-
otics [9].
In this prospective observational study, it was our aim to evaluate
the achievement of target concentrations in the context of empiric con-
tinuous infusion TZP and MER therapy in critically ill patients.2. Patients and methods
2.1. Patients
This prospective observational study was conducted in the Depart-
ment of Intensive Care Medicine of Ghent University Hospital (Ghent,
Belgium). Ethical approval was obtained from the Ghent University
Hospital Ethics Committee (registration number 2016/0264). The
need for informed consent was waived by the Ethics Committee. Pa-
tients were eligible for inclusion if they were admitted to the surgical
ICU and received either TZP or MER in continuous infusion. Patients
younger than 18 years and patients receiving extracorporeal membrane
oxygenation (ECMO) or renal replacement therapy (RRT) during antibi-
otic therapy were excluded from analysis. Only one antibiotic episode
per patient (either TZP or MER) was recorded. TZP dosing was as fol-
lows: measured creatinine clearance (CLCR) b15 mL/min: 8/1 g /24 h,
CLCR 15–29 mL/min: 12/1.5 g /24 h and for a CLCR ≥ 30 mL/min 16/
2 g/24 h was prescribed. MER dosing was as follows: CLCR
b 15 mL/min: 1 g /24 h, CLCR 15–29 mL/min: 2 g /24 h and for a CLCR
≥ 30 mL/min, a dosing regimen of 3 g /24 h was used. All patients re-
ceived a loading dose, 4/0.5 g /30 min for TZP and 1 g /30 min for
MER, immediately prior to the initiation of the continuous infusion reg-
imen. CLCR was determined by measuring urinary creatinine clearance
concentrations in an 8-h urinary collection using an indwelling urinary
catheter. Additional data such as additional biochemistry, demographic
data, the modiﬁed Sequential Organ Failure Assessment score (SOFA),
the Acute Physiology and Chronic Health Evaluation (APACHE II) score
on admission ICU and hospital survival were prospectively recorded.2.2. Bioanalysis of TZP and MER plasma concentrations
A residual sample of 3mL blood gas tubes (lithiumheparin blood gas
tubes, Siemens, Tarrytown, USA) was sent to the core laboratory of the
Dept. of Laboratory Medicine at Ghent University Hospital where they
were ﬁrst stored in a refrigerator at 4 °C until they were collected by
the toxicology laboratory technicians. Storage at 4 °C was never longer
than 24 h. After transferring to an Eppendorf tube, plasma samples
were centrifuged at 16162 ×g for 8 min (Microfuge 16, Beckman Coul-
ter, Brea, California). Immediately afterwards, the plasma samples
were stored at−80 °C until analysis. All samples were analyzed within
3 months. The total (bound+unbound) plasma concentration of piper-
acillin (PIP) andMERwasdetermined byultra-performance liquid chro-
matography tandem mass spectrometry (UPLC – MS/MS). Tazobactam
concentrationswere not analyzed in this study. The lower limit of quan-
tiﬁcation (LLOQ) for PIP and MER was 1.5 mg/L and 1.1 mg/L respec-
tively [10].2.3. Deﬁnition of target attainment
The lower limit of the target window was deﬁned based on the epi-
demiological cutoff value (ECOFF). The ECOFF of P. aeruginosa, one of the
most common gram-negative bacteria isolated in ICU patients, wasused
for both TZP (ECOFF of 16 mg/L) and MER (ECOFF of 2 mg/L) [11,12].
These cutoff values represent a worst-case scenario for empirical dosing
and are equal to the clinical breakpoints for P. aeruginosa as published
by the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) [11]. As theMIC value of an individual strain often poorly rep-
resents true antimicrobial susceptibility, Mouton, et al [13] have recom-
mended to consider MICs from a distribution point of view for target
attainment calculation in individual patients. An MIC result within a
range of valueswith the epidemiological cut-off as upper limit, indicates
that it is within the wild-type distribution. It is therefore reasonable to
use the ECOFF as value to calculate target attainment for empirical dos-
ing regimens. Therefore, a minimum unbound concentration of 100%
fT≥4xECOFF, i.e. 64 mg/L for TZP and 8 mg/L for MER, was adopted as
lower limit of the target range as recommended by experts [5]. The per-
centage of target attainmentwith 100% fT≥1xECOFF and 100% fT≥2xECOFF as
lower limit was also reported.
Despite the fact that beta-lactam antibiotics are usually considered
to be safe, high concentrations may cause toxicity [9]. Quinton, et al
[14] deﬁned a threshold for neurotoxicity of 157 mg/L for TZP when in-
fused continuously in ICU patients. To our knowledge, there is no data
on toxicity of continuously infusedMER. Imani, et al [9] evaluated inter-
mittent infusion MER and correlated neurotoxicity to through concen-
trations (Cmin) of 64.2 mg/L and nephrotoxicity to Cmin levels of
44.45 mg/L for MER. Based on this data, an unbound TZP concentration
of 160 mg/L and an unbound MER concentration of 45 mg/L was
adopted as upper limit of the therapeutic window for both TZP and
MER continuous infusion concentrations.
The achievement of target concentrations, i.e. unbound concentra-
tions within the predeﬁned target window, of empirically dosed TZP
andMERwas evaluated during the ﬁrst 2 days (i.e. 48 h) of therapy, as-
suming that usually no or fewmicrobiology results are available within
this timeframe.
Aswemeasured only total concentrations of both PIP andMER, anal-
yses were performed with calculated free or unbound concentrations.
We assumed a level of protein binding of 30% for PIP and 2% for MER,
which was previously deemed appropriate [15,16].2.4. Statistical analysis
All statistical analyses were performed using R (version 3.4.2; Insti-
tute for Statistics and Mathematics[http://www.r-project.org/])) and
RStudio (version 1.1.383; RStudio, Inc. Boston, MA, USA). Continuous
variables are presented as mean and standard deviation (SD) for nor-
mally distributed data and as median and interquartile range (IQR) for
non-normally distributed data. Categorical variables are presented as
percentages (%). The Students' t-test was used to compare normally
distributed continuous variables, while the Mann-Whitney U test was
used to compare non-normally distributed continuous variables. Differ-
ences between categorical variables were evaluated by the Pearson
Chi-square test or Fischer's exact test as appropriate. The within-
patient coefﬁcient of variation (CV) was calculated by computing the
standard deviation (SD)/mean ratio of all antibiotic concentrations per
patient. Multivariable logistic regression was used to predict target at-
tainment of empirical dosing TZP and MER within the ﬁrst 2 days of
therapy. Predeﬁned predictors of target attainment were derived from
TZP and MER PK/PD literature and included estimated creatinine clear-
ance (Cockroft-Gault), total body weight, albumin concentration and
APACHE II score [17-24]. Type of antibiotic (either TZP or MER) was
also included as predictor. A p-value b0.05 was considered signiﬁcant.
Bootstrapping (n = 1E5) of the conﬁdence intervals was undertaken
Table 2
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3. Results
3.1. Patient characteristics
In total, 253 patients, 164 (64.8%) of which were male, were in-
cluded for analysis. The mean (SD) age of the patients was 62.2 (15)
years and the mean (SD) APACHE II score upon admission was 23.5
(8.4). Median (IQR) SOFA score was 5 (0–9). Median (IQR) CLCR was
74.7 (31.1–128.9) mL/min. The majority of patients were admitted for
surgical emergencies (50.6%), while 43.1%, 5.5% and 0.4% percent were
admitted for medical emergencies, trauma or burns respectively. Of
these 253 patients, 205 (81%) received TZP and 48 (19%) received
MER. Out of all patients, 217 (85.6%) survived their ICU stay and 189
(74.7%) patientswere alive at the end of their hospital stay. Free concen-
trations of continuous infusion PIP ranged from 11 mg/L to 422.8 mg/L,
while free concentrations of continuous infusion MER ranged from
2.03 mg/L to 57.7 mg/L. Table 1 represents a univariable analysis of ad-
mission, demographic, laboratory and disease severity data for patients
receiving TZP versus patients receiving MER. Patients receiving TZP
weighed less, had a lower APACHEII score upon admission, a lower
SOFA score at time of sampling, a lower estimated creatinine clearance,
a shorter duration of therapy, a shorter length of ICU stay and a higher
ICU and hospital survival when compared to patients receiving MER.
3.2. Target concentrations of empirical dosed TZP and MER during the ﬁrst
2 days of therapy
Overall, 141 (55.8%) had one (or two) plasma samples with an anti-
biotic free concentration that did not fall within the predeﬁned target
window with 100% fT≥4xECOFF as lower limit, i.e. 64–160 mg/L and
8–45 mg/L for PIP and MER respectively. More speciﬁcally, 129
(62.9%) of the 205patients receiving TZP and 12 (25%) of the 48patients
receiving MER had free concentrations outside the target range. These
proportions (62.9% for TZP and 25% for MER) were signiﬁcantly differ-
ent (χ2 = 21.16, df = 1, p-value ≤0.001).Table 1
Univariable analysis of patients receiving piperacillin/tazobactam versus patients receiv-
ing meropenem.
Variable TZP (n= 205) MER (n= 48) p-value
Age (yr), mean, SD 62.4 (15.5) 63 (12.7) 0.781
Gender, male (%) 129 (62.9%) 35 (72.9%) 0.192
Weight (kg), mean, SD 74.6 (16.1) 82.8 (18.7) 0.006
Height (cm), mean, SD 170.3 (15.1) 173 (9.8) 0.125
APACHE II, mean, SD 22.9 (8.1) 26 (9.3) 0.036
SOFA, median, IQR 4 (0–8) 7 (3−11) 0.005
Serum creatinine (mg/dL), median, IQR 0.8 (0.6–1.2) 0.8 (0.5–1.1) 0.371
CLCR (mL/min), mean, SD 102.1 (63.3) 89.3 (82.4) 0.347
Estimated creatinine clearance
(mL/min), mean, SD
95.4 (58.3) 117.8 (68.2) 0.034
Vasopressive therapy, yes (%) 0% 2.1% 0.093
Fluid balance (mL), mean, SD 1303.9
(1751.1)
1549.5
(1882.9)
0.413
Duration of therapy (days), median, IQR 3 (2–5) 5 (2–8) 0.013
ICU length of stay (days), 6 (3−12) 9 (4–19) 0.049
ICU survival (%) 181 (88.3%) 36 (75%) 0.017
Hospital survival (%) 164 (80%) 25 (52.1%) b0.001
Admission category (%)
Medical 82 27 0.059
Surgical 110 19 0.111
Trauma 13 1 0.48
Burns 0 1 0.190
CLCR =measured creatinine clearance (mL/min). Estimated creatinine clearance was cal-
culated using the Cockcroft-Gault formula.Most of the patients not achieving predeﬁned target free concentra-
tions had free concentrations below the lower limit of the target range,
i.e. 120 out of 253 (47.4%) patients.More speciﬁcally, of the 129 TZP and
12 MER patients with free concentrations outside the predeﬁned win-
dow, 110 (85.3%) TZP patients and 10 (83.3%) MER patients had one
or more free concentrations below 64 mg/L for TZP and below 8 mg/L
for MER.
According to univariable analysis, patients not achieving target free
concentrations were younger, more likely to be trauma patients and
more likely to survive their hospital stay. These patients also had a
slightly lower APACHE II score upon admission, a lower SOFA score on
the day of sampling, a lower serum creatinine, a larger positive ﬂuid bal-
ance, a higher CLCR and a higher estimated creatinine clearance (using
the Cockroft-Gault formula) (Table 2).
When the lower limit of the target range was set to 100% fT≥2xECOFF,
the percentage of patients with free concentrations not within the tar-
get window was 18.2% (20.9% of the patients receiving TZP and 6.3%
of the patients receiving MER). When 100% fT≥1xECOFF was deﬁned as
the lower limit, the percentage of the total number of patients that did
not achieve target free concentrations within the predeﬁned target
range further dropped to 16.2%, with 19.5% for TZP patients and 2.1%
for MER patients.
Multivariable logistic regression identiﬁed estimated creatinine
clearance (Cockroft-Gault) as signiﬁcant predictor of target attainment.
Increasing creatinine clearance decreases the chances of achieving tar-
get free concentrations. Multivariable analysis also demonstrated that
patients receiving MER were more likely to achieve target free concen-
trationswhen compared to patients receiving PIP. Other predeﬁned var-
iables (weight, APACHE II score and albumin) were no signiﬁcant
predictors of target attainment (Table 3).
4. Discussion
Achievement of target concentrations (unbound PIP concentrations
between 64 and 160 mg/L and unbound MER concentrations between
8 and 45 mg/L) during the ﬁrst two days of continuous infusion TZP
(16/2 g /24 h) or MER (3 g /24 h) therapy was b40% for TZP andUnivariable analysis for patients (not) achieving target concentrations within the ﬁrst
2 days of therapy.
Variable Non-TA (n= 141) TA (n= 112) p-value
Age (yr), mean, SD 59 (16.2) 67 (11.9) b0.001
Gender, male (%) 91 (64.5%) 73 (65.2%) 0.916
Weight (kg), mean, SD 76.3 (16.2) 76.1 (17.7) 0.912
Height (cm), mean, SD 172 (9.92) 169 (18.3) 0.096
APACHE II, mean, SD 22.2 (8.13) 25.1 (8.49) 0.007
SOFA, median, IQR 3 (0–7) 6 (0−11) b0.001
Serum creatinine (mg/dL),
median, IQR
0.69 (0.51–0.92) 0.89
(0.664–1.37)
b0.001
CLCR, mean, SD (mL/min) 124.4 (74) 68.6 (40.5) b0.001
Vasopressive therapy, yes (%) 0% 0.9% 1
Fluid balance (mL), mean, SD 978.3 (1591.5) 1819.1
(1888.3)
b0.001
Estimated CLCR, mean, SD
(mL/min)
112.8 (63.2) 83.1 (53.5) b0.001
Duration of therapy (days),
median, IQR
3 (2–5) 3 (2–6) 0.480
ICU length of stay (days),
median, IQR
6 (3–14) 6 (3−13) 0.313
ICU survival (%) 126 (89.4%) 91 (81.3%) 0.067
Hospital survival (%) 116 (82.3%) 73 (65.2%) 0.002
Admission category (%)
Medical 64 (45.4%) 45 (40.2%) 0.482
Surgical 64 (45.4%) 64 (57.1%) 0.084
Trauma 12 (8.51%) 2 (1.79%) 0.025
Burns 0 (0%) 1 (0.892%) 0.443
CLCR =measured creatinine clearance (mL/min). Estimated creatinine clearance was cal-
culated using the Cockroft-Gault formula. Non-TA = non-target attainment, TA = target
attainment.
Table 3
Multivariable logistic regression for target attainment of empirically dosed piperacillin/tazobactam and meropenem.
Predictors Coefﬁcients (SE) Odds ratio Bootstrapped 95% CI for odds ratio p-value
Estimated creatinine clearance (mL/min) −0.012 (0.0029) 0.988 0.982;0.994 b0.001
Weight (kg) −0.0067 (0.0009) 0.993 0973;1.01 0.436
Albumin (mg/dL) −0.028 (0.023) 0.971 0.926;1.02 0.198
APACHE II score 0.0256 (0.018) 1.026 0.989;1.06 0.141
AB type 1.79 (0.501) 6.016 2.12;18.4 b0.001
SE= standard error, CI = conﬁdence interval, Estimated creatinine clearance was calculated using the Cockcroft-Gault formula, AB type = type of antibiotic (TZP was coded 1 and MER
was coded 2).
R2 = 0.16 (Hosmer-Lemeshow), 0.2 (Cox-Snell), 0.261 (Nagelkerke). Model χ2 = 54.6, p ≤0.0001.
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ill patients. Estimated creatinine clearancewas identiﬁed as a risk factor
for target non-attainment, which is in accordance with earlier ﬁndings
[7,24].
Reaching therapeutic antibiotic concentrations in a timelymanner is
crucial when treating ICU patients with severe infections as inappropri-
ate antibiotic dosing has been linked to adverse infection outcomes
[4,5]. Critically ill patients, because of the profound PK alterations docu-
mented in these patients, are at risk for low target attainment when
beta-lactam antibiotics are infused intermittently (i.e. bolus to 30 min
i.v. infusion) [5,25]. Prolonging the duration of beta-lactamantibiotic in-
fusion has shown the potential to achieve higher target attainment rates
compared to intermittent bolus dosing [16].
The results of this study demonstrate that, even with continuous in-
fusion, a signiﬁcant number of ICU patients does not achieve target ther-
apeutic free concentrations with standard doses of TZP. Likewise,
colleagues Carrié, et al [26] documented that 19% of their patients re-
ceiving continuous infusion TZP (16 g/24 h) did not achieve free con-
centrations of 100% fTNMIC. To the best of our knowledge, there is no
data describing target attainment in ICU patients receiving continuous
infusion meropenem during the ﬁrst two days of therapy. In this
study, patients receiving MER were more likely to achieve target un-
bound concentrations when compared with patients receiving TZP.
Nevertheless, patients receiving MER did not have a signiﬁcantly
lower renal clearance when compared to patients receiving TZP
(Table 1). While there is no consensus in literature, some authors
have suggested that piperacillin has non-linear (as opposed to linear)
kinetics and both active tubular secretion and glomerular ﬁltration are
considered to contribute to the renal elimination of this drug [27]. Col-
leagues Vinks, et al [27] documented a signiﬁcantly higher piperacillin
clearance during continuous infusion when compared with clearance
during intermittent infusion in a cross-over PK study with eight cystic
ﬁbrosis patients. Following this hypothesis, extrapolating piperacillin
drug clearance values from intermittent infusion dosing regimens may
lead to over prediction of piperacillin concentrationswhen infused con-
tinuously. Active tubular secretion has also been documented for
meropenem [28]. However, there are no PK studies at handdemonstrat-
ing saturable elimination of meropenem, indicating that saturation of
meropenem elimination might not happen at clinically relevant
concentrations.
To optimize target attainment rates of empirical beta-lactam
dosing regimens during the initial phase of antibiotic therapy, sev-
eral solutions are available. For example, software guided PK/PD
dose-optimization uses population pharmacokinetic modeling
combined with Bayesian forecasting to predict antibiotic concen-
trations [6,23]. This approach is able to estimate the effect of differ-
ent patient covariates (e.g. creatinine clearance) on target
attainment. When no previous antibiotic concentrations are avail-
able (e.g. when initiating therapy), this approach may allow us to
use a more patient-tailored approach for empirical dosing. In re-
cent studies, this approach has been improved by involving thera-
peutic drug monitoring (TDM) in the process [29]. PK/PD dosing
software combined with TDM and adaptive feedback is probably
even more suited to achieve and maintain target concentrations.This strategy is especially useful for ﬁne-tuning a dosing when
therapy is initiated and as soon as antibiotic concentrations are
available. It is important to note however that, at this time, there
is no evidence of improved clinical outcomes when TDM of beta-
lactam antibiotics is used.
This study has several limitations. First, the effect of inappropri-
ate antibiotic concentrations in the early phase of sepsis or septic
shock on clinical outcome was not assessed in this study, nor in the
study by Carrié et al [26]. While delay of appropriate antibiotic ther-
apy is expected to lead to adverse infection outcomes, a ﬁrm link be-
tween low beta-lactam antibiotic concentrations and inferior clinical
outcome has not yet been demonstrated. In this study, the aim was
to describe clinical target attainment of empirically dosed, continu-
ously infused TZP and MER in ICU patients. Empirical dosing regi-
mens are designed to achieve antibiotic concentrations high
enough to kill all bacteria deemed susceptible to the drug and as-
suming a worst-case scenario when no MIC data is available is there-
fore a pragmatic approach [4].
For the purpose of this study, plasma concentrations were mea-
sured as a substitute for tissue concentrations. Infection usually oc-
curs in the interstitial ﬂuid of tissues and it is the concentration of
TZP or MER that reaches the site of infection that is of importance.
This is a signiﬁcant limitation as in critically ill patients, tissue pen-
etration may be variable and therefore therapeutic plasma
concentrations do not necessarily predict therapeutic tissue con-
centrations [30].
Third, no unbound TZP or MER concentrations were measured. Only
the unbound fraction of the antimicrobial drug is able to exert its anti-
bacterial effect. Therefore, a level of 30% and 2% protein bindingwas as-
sumed for TZP and MER respectively, which was previously deemed
appropriate [15,16]. Also, there is little consensus on the preferred PK/
PD target for beta-lactam antibiotics [5]. Carrié, et al [26] adopted a PD
target of 100% fT≥MIC. However, the PD target of 100% fT≥MIC should
probably be regarded as a minimum target for continuous infusion as
concentrationswill be either above or below theMIC for the entire dos-
ing interval when a PD target of 100% fT≥MIC is applied. Last, because
some blood gas tubes were thrown away by accident before they
were sent to the laboratory of toxicology, especially when initiating
the study, not all patients had samples available for analysis on all
days of TZP or MER therapy.
In conclusion, achieving target therapeutic concentrations in criti-
cally ill patients with standard, empiric dosing of MER (3 g /24 h), and
especially TZP (16/2 g /24 h), remains highly challenging, despite opti-
mization of the mode of infusion.
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